Clinical and genomic landscape of RAS mutations in gynecologic cancers.
Ji SonYingao ZhangHeather Y LinOriol MirallasPablo Álvarez BallesterosMirella NardoNatalie ClarkRobert Tyler HillmanErick CampbellVijaykumar HollaAmber M JohnsonAmadeo B BiterYing YuanLauren P CobbDavid M GershensonAmir A JazaeriKaren H LuPamela T SolimanShannon Neville WestinElizabeth D EuscherBarrett C LawsonRichard K YangFunda Meric-BernstamDavid S HongPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
RAS mutations in gynecologic cancers have a distinct histopathologic distribution and may impact overall survival. PIK3CA, PTEN, and ARID1A are potentially actionable co-alterations. RAS pathway-targeted therapy should be considered.